Generality Assessment of a Model Considering Heterogeneous Cancer Cells for Predicting Tumor Control Probability for Stereotactic Body Radiation Therapy Against Non-Small Cell Lung Cancer

Ryo Saga; Yusuke Matsuya; Hideki Obara; Fumio Komai; Hironori Yoshino; Masahiko Aoki; Yoichiro Hosokawa

doi:10.1016/j.adro.2023.101437

Generality Assessment of a Model Considering Heterogeneous Cancer Cells for Predicting Tumor Control Probability for Stereotactic Body Radiation Therapy Against Non-Small Cell Lung Cancer

Adv Radiat Oncol. 2024 Jan 1;9(4):101437. doi: 10.1016/j.adro.2023.101437. eCollection 2024 Apr.

Authors

Ryo Saga¹, Yusuke Matsuya^{2

3}, Hideki Obara⁴, Fumio Komai⁴, Hironori Yoshino¹, Masahiko Aoki⁵, Yoichiro Hosokawa¹

Affiliations

¹ Department of Radiation Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, Japan.
² Nuclear Science and Engineering Center, Research Group for Radiation Transport Analysis, Japan Atomic Energy Agency, Tokai, Japan.
³ Faculty of Health Sciences, Hokkaido University, Sapporo, Japan.
⁴ Department of Radiology, Division of Medical Technology, Hirosaki University School of Medicine and Hospital, Hirosaki, Japan.
⁵ Department of Radiation Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Abstract

The generality of a model for predicting tumor control probability from in vitro clonogenic survival considering of cancer stem-like cells, the so-called integrated microdosimetric-kinetic model, is presented by comparing the model to public data on stereotactic body radiation therapy for non-small cell lung cancer cells.